<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349296</url>
  </required_header>
  <id_info>
    <org_study_id>BARIS</org_study_id>
    <nct_id>NCT01349296</nct_id>
  </id_info>
  <brief_title>BIBF 1120 and RAD001 in Solid Tumors - Phase I</brief_title>
  <acronym>BARIS</acronym>
  <official_title>BARIS - BIBF1120 and RAD001 in Solid Tumors. A Phase I Trial to Evaluate the Safety and Tolerability of Combined BIBF 1120 and RAD001 in Solid Tumors and to Determine the Maximum Tolerated Dose (MTD) of the Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIBF1120 and RAD001 in solid tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in&#xD;
      solid tumors and to determine the maximum tolerated dose (MTD) of the combination&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) of RAD001 in combination with BIBF 1120 (150mg bid or 200mg bid) (endpoint: dose-limiting toxicities)</measure>
    <time_frame>Every visit</time_frame>
    <description>Documentation an estimation of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the tolerability of BIBF1120 and RAD001 in combination (endpoints: assessment of adverse events (AEs) according to CTC-AE V4.0)</measure>
    <time_frame>Every visit during the study</time_frame>
    <description>Documentation an estimation of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the clinical efficacy of the combination descriptively (endpoints: RR, progression free survival (PFS), overall survival (OS))</measure>
    <time_frame>Baseline and every six weeks during the study, after study every 6 months</time_frame>
    <description>CT will be done for evaluation of RR and PFS on day 57 and then every 6 weeks until progression.&#xD;
For overall survival a telephone call every six months after study is continuation will be done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze individual BIBF1120 pharmacokinetic (PK) parameters at steady-state (ss) of monotherapy and PK parameters of both BIBF1120 and RAD001 at ss of combination</measure>
    <time_frame>day 14, day 29</time_frame>
    <description>Blood collection for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in tumor vasculature a) early under BIBF1120 monotherapy, b) at ss of BIBF1120 monotherapy and c) at ss of combination therapy using dynamic contrast-enhanced MRI (DCE-MRI) (endpoints: IAUC, Ktrans, Kep, Ve)</measure>
    <time_frame>baseline, day 3, day 14, day 29</time_frame>
    <description>DCE MRI will be done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the clinical outcome with FGFR1-amplification status (endpoints: see above for clinical parameters)</measure>
    <time_frame>Screening</time_frame>
    <description>Documentation of histology</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>BIBF 1120 + RAD001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus + BIBF 1120</intervention_name>
    <description>Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d</description>
    <arm_group_label>BIBF 1120 + RAD001</arm_group_label>
    <other_name>Everolimus, RAD001, Afinitor, BIBF 1120</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically proven solid tumor disease after failure of standard&#xD;
             therapy regimen(s)&#xD;
&#xD;
          2. Age &gt; 18 years.&#xD;
&#xD;
          3. ECOG performance status 0 to 1.&#xD;
&#xD;
          4. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          5. Subjects with at least one measurable (CT or MRI) lesion.&#xD;
&#xD;
          6. Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements conducted within 7 days prior to screening:&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 g/dl&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt;1,500/mm3&#xD;
&#xD;
               -  Platelet count ³ 100,000/μl&#xD;
&#xD;
               -  Total bilirubin within normal limits&#xD;
&#xD;
               -  ALT and AST &lt; 1.5 x upper limit of normal ( or &lt; 2.5 x upper limit of normal in&#xD;
                  patients with liver involvement)&#xD;
&#xD;
               -  PT-INR/PTT &lt; 1.5 x upper limit of normal [Patients who are being therapeutically&#xD;
                  anticoagulated with an agent such as coumadin or heparin will be allowed to&#xD;
                  participate provided that no prior evidence of underlying abnormality in these&#xD;
                  parameters exists.]&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 x upper limit of normal or creatinine clearance (CrCl) ≥&#xD;
                  50 ml/min calculated by either Cockcroft-Gault or by 24 hours urine collection&#xD;
&#xD;
          7. More than 14 days since previous chemotherapy, radiotherapy and surgery&#xD;
&#xD;
          8. Negative urine or serum HCG in women of childbearing potential&#xD;
&#xD;
          9. Signed and dated informed consent before the start of specific protocol procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Limited number of prior lines of treatment (including surgery and radiotherapy, if&#xD;
             part of the standard therapy of the respective tumor entity)&#xD;
&#xD;
          2. Prior treatment with BIBF 1120 or any other VEGFR inhibitor (bevacizumab is allowed)&#xD;
&#xD;
          3. Prior treatment with RAD001 or any other mTOR inhibitor&#xD;
&#xD;
          4. Known hypersensitivity to the trial drugs, to their excipients or to contrast media&#xD;
&#xD;
          5. Chemo-, hormono-, radio-(except for brain and extremities) or immunotherapy or therapy&#xD;
             with monoclonal antibodies or small tyrosine kinase inhibitors within the past 2 weeks&#xD;
             prior to treatment with the trial drugs&#xD;
&#xD;
          6. Persistence of clinically relevant therapy related toxicity from previous chemo and/or&#xD;
             radiotherapy&#xD;
&#xD;
          7. Active brain metastases (e.g. stable for &lt;4 weeks, no adequate previous treatment with&#xD;
             radiotherapy, symptomatic, requiring treatment with anticonvulsants; dexamethasone&#xD;
             therapy will be allowed if administered as stable dose for at least one month before&#xD;
             trial drug administration) or leptomeningeal metastases (documented by lumbar&#xD;
             puncture)&#xD;
&#xD;
          8. History of cardiac disease: congestive heart failure &gt;NYHA class 2; active coronary&#xD;
             artery disease (CAD), (MI more than 6 mo prior to study entry is allowed); cardiac&#xD;
             arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted)&#xD;
             or uncontrolled hypertension&#xD;
&#xD;
          9. Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter the absorption of BIBF1120 or RAD001 (e.g. ulcerative disease,&#xD;
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel&#xD;
             resection)&#xD;
&#xD;
         10. History of HIV infection or previously seropositive for the virus&#xD;
&#xD;
         11. History of Hepatitis B or/and C or previously seropositive for the Hepatitis B or/and&#xD;
             C virus&#xD;
&#xD;
         12. Radiographic evidence of cavitary or necrotic tumors&#xD;
&#xD;
         13. Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of&#xD;
             major blood vessels&#xD;
&#xD;
         14. Treatment with other investigational drugs or treatment in another clinical trial&#xD;
             within the past 30 days before start of therapy or concomitantly with the trial&#xD;
&#xD;
         15. Patients with seizure disorder requiring enzyme-inducing antiepileptics&#xD;
&#xD;
         16. Therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed&#xD;
             for maintenance of an indwelling intravenous devise) or antiplatelet therapy (except&#xD;
             for low-dose therapy with acetylsalicylic acid ≤325mg per day)&#xD;
&#xD;
         17. Major injuries within the past 10 days prior to start of study treatment with&#xD;
             incomplete wound healing and/or planned surgery during the on-treatment study period&#xD;
&#xD;
         18. Evidence or history of bleeding diasthesis or thrombosis, and known inherited&#xD;
             predisposition to bleeding or thrombosis&#xD;
&#xD;
         19. Proteinuria CTC AE grade 2 or greater&#xD;
&#xD;
         20. Active serious infections&#xD;
&#xD;
         21. Patients undergoing renal dialysis&#xD;
&#xD;
         22. Previous or concurrent cancer that is distinct in primary site or histology from the&#xD;
             cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal&#xD;
             cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively&#xD;
             treated &gt; 3 years prior to study entry&#xD;
&#xD;
         23. Serious illness or concomitant non-oncological disease such as neurologic,&#xD;
             psychiatric, infectious disease or active ulcers (gastrointestinal tract, skin) or&#xD;
             laboratory abnormality that may increase the risk associated with study participation&#xD;
             or study drug administration and in the judgment of the investigator would make the&#xD;
             patient inappropriate for entry into the study&#xD;
&#xD;
         24. Patients who are sexually active and unwilling to use a medically acceptable method of&#xD;
             contraception (e.g. such as implants, injectables, combined oral contraceptives, some&#xD;
             intrauterine devices or vasectomized partner for participating females, condoms for&#xD;
             participating males) during the trial and for at least three months after end of&#xD;
             active therapy&#xD;
&#xD;
         25. Pregnancy or breast feeding&#xD;
&#xD;
         26. Psychological, familial, sociological or geographical factors potentially hampering&#xD;
             compliance with the study protocol and follow-up schedule&#xD;
&#xD;
         27. Active alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Wolf, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2011</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lung Cancer Group Cologne</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Juergen Wolf</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

